C19H14BrFeN, monoclinic, P21/c (no. 14), a = 9.8612(3) Å, b = 13.8034(5) Å, c = 11.3372(5) Å, ( = 90.072(3)°, V = 1543.2 Å3, Z = 4, Rgt(F) = 0.0350, wRref(F2) = 0.0746, T = 291 K
C11H7BrO4, triclinic, P1̄ (no. 2), a = 4.3164(5) Å, b = 10.7922(12) Å, c = 11.1521(11) Å, α = 98.075...
C13H12FeN2O, monoclinic, P21/n (no. 14), a = 5.9035(2) Å, b = 20.7111(6) Å, c = 9.1403(3) Å, β = 90....
C16H12F3NO, orthorhombic, P212121 (no. 19), a = 6.9928(6) Å, b = 8.9764(8) Å, c = 21.216(2) Å, V = 1...
C6H4Br2FN, monoclinic, P21/c (no. 14), a = 17.0332(5) Å, b = 4.34070(10) Å, c = 21.9732(5) Å, β = 10...
C21H21FeNO, monoclinic, P121/a1 (no. 14), a = 7.329(7) Å, b = 17.343(3) Å, c = 13.618(5) Å, ? = 95.0...
In the title compound, [Fe(C5H5)(C33H25BrN3O)], the fused four-ring system, 11H-indeno[1,2-b]quinoxa...
WOS: 000234198700025C21H21FeNO, monoclinic, P12(1)/alpha 1 (no. 14), a = 7.329(7) angstrom, b = 17.3...
R factor = 0.053; wR factor = 0.137; data-to-parameter ratio = 15.6. In the title compound, [Fe(C5H5...
C15H11ClFN3O2, monoclinic, P21/c (no. 14), a = 12.9430(8) Å, b = 9.3196(5) Å, c = 12.5959(8) Å, β = ...
Biferrocenyi, C₅H₅,Fe,C₅H₄. C₅H₄ .Fe.C₅H₅., crystallises in the monoclinic system with a = 10.35, b ...
C19H17FeN3O4S, triclinic, P1̄ (no. 2), a = 7.1964(3) Å, b = 10.9732(4) Å, c = 11.6391(4) Å, α = 80.8...
The title compound, [Fe(C5H5)(C8H13N)]Br, is isotypic with the analogous chloride compound. The Fe&a...
In the title compound, [Fe(C5H5)(C34H28N3O)], the four-fused-rings system of the 11H-indeno[1,2-b]qu...
C17H15IN2O, monoclinic, C2 (no. 5), a = 23.6958(12) Å, b = 5.5334(2) Å, c = 15.9712(9) Å, β = 132.32...
In the title compound, C19H17BrO3, the ring skeleton is located on a crystallographic mirror plane; ...
C11H7BrO4, triclinic, P1̄ (no. 2), a = 4.3164(5) Å, b = 10.7922(12) Å, c = 11.1521(11) Å, α = 98.075...
C13H12FeN2O, monoclinic, P21/n (no. 14), a = 5.9035(2) Å, b = 20.7111(6) Å, c = 9.1403(3) Å, β = 90....
C16H12F3NO, orthorhombic, P212121 (no. 19), a = 6.9928(6) Å, b = 8.9764(8) Å, c = 21.216(2) Å, V = 1...
C6H4Br2FN, monoclinic, P21/c (no. 14), a = 17.0332(5) Å, b = 4.34070(10) Å, c = 21.9732(5) Å, β = 10...
C21H21FeNO, monoclinic, P121/a1 (no. 14), a = 7.329(7) Å, b = 17.343(3) Å, c = 13.618(5) Å, ? = 95.0...
In the title compound, [Fe(C5H5)(C33H25BrN3O)], the fused four-ring system, 11H-indeno[1,2-b]quinoxa...
WOS: 000234198700025C21H21FeNO, monoclinic, P12(1)/alpha 1 (no. 14), a = 7.329(7) angstrom, b = 17.3...
R factor = 0.053; wR factor = 0.137; data-to-parameter ratio = 15.6. In the title compound, [Fe(C5H5...
C15H11ClFN3O2, monoclinic, P21/c (no. 14), a = 12.9430(8) Å, b = 9.3196(5) Å, c = 12.5959(8) Å, β = ...
Biferrocenyi, C₅H₅,Fe,C₅H₄. C₅H₄ .Fe.C₅H₅., crystallises in the monoclinic system with a = 10.35, b ...
C19H17FeN3O4S, triclinic, P1̄ (no. 2), a = 7.1964(3) Å, b = 10.9732(4) Å, c = 11.6391(4) Å, α = 80.8...
The title compound, [Fe(C5H5)(C8H13N)]Br, is isotypic with the analogous chloride compound. The Fe&a...
In the title compound, [Fe(C5H5)(C34H28N3O)], the four-fused-rings system of the 11H-indeno[1,2-b]qu...
C17H15IN2O, monoclinic, C2 (no. 5), a = 23.6958(12) Å, b = 5.5334(2) Å, c = 15.9712(9) Å, β = 132.32...
In the title compound, C19H17BrO3, the ring skeleton is located on a crystallographic mirror plane; ...
C11H7BrO4, triclinic, P1̄ (no. 2), a = 4.3164(5) Å, b = 10.7922(12) Å, c = 11.1521(11) Å, α = 98.075...
C13H12FeN2O, monoclinic, P21/n (no. 14), a = 5.9035(2) Å, b = 20.7111(6) Å, c = 9.1403(3) Å, β = 90....
C16H12F3NO, orthorhombic, P212121 (no. 19), a = 6.9928(6) Å, b = 8.9764(8) Å, c = 21.216(2) Å, V = 1...
DOI
Add to ORKG